R McKay1,2, B Haider3, M S Duh3, A Valderrama4, M Nakabayashi1, M Fiorillo1, L Ristovska3, L Wen4, P Kantoff1,5. 1. Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. 2. Division of Hematology/Oncology, University of California, Moores Cancer Center, San Diego, CA, USA. 3. Analysis Group, Inc., Boston, MA, USA. 4. Bayer Healthcare Pharmaceuticals, Wayne, NJ, USA. 5. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
BACKGROUND: Data regarding the impact of symptomatic skeletal events (SSEs) on health economics and patient-reported outcomes in men with castration-resistant prostate cancer (CRPC) and bone metastases from a clinical setting are lacking. Hence, this study aimed to quantify the effects of SSEs on health-care resource utilization (HRU), health-related quality of life (HRQoL) and pain in men with CRPC metastasized to bone. METHODS: This cohort study included men with CRPC and bone metastasis treated at a tertiary center during December 1996-July 2015. SSEs, including pathological fracture, radiation to bone, spinal cord compression and bone surgery, as well as HRU were identified retrospectively through medical records and clinical database. A subset of surviving patients completed Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Brief Pain Inventory-Short Form (BPI-SF) questionnaires. The incremental effect of SSEs on HRU was evaluated using multivariable generalized linear regression. Questionnaire scores were compared using effect sizes (ES); ES⩾0.33 indicated meaningful differences between SSE and non-SSE cohorts. Lower scores suggest lower HRQoL and pain. RESULTS: Of the 832 patients, 207 developed ⩾1 SSE (mean 1.5±0.8) during follow-up (median 2.1 years). Radiation to bone was the most common SSE (84.1%). SSE cohort had significantly higher emergency room (incidence rate ratio (IRR)=1.48; P=0.006), outpatient (IRR=1.17; P=0.005) and inpatient (IRR=1.74; P<0.001) visits. Of the 107 eligible survey patients, 103 (96.3%) responded. SSE cohort had lower mean FACT-P functional well-being (17.5 vs 19.8; P=0.158; ES=0.36), higher mean pain severity (2.5 vs 1.6; P=0.048; ES=0.47) and worst pain scores (3.6 vs 2.3; P=0.033; ES=0.50) compared with the non-SSE cohort, indicating meaningful differences between cohorts. CONCLUSIONS: This study demonstrated high economic and HRQoL burden of SSEs. The findings underscore the need for better supportive and disease-modifying treatments for these patients.
BACKGROUND: Data regarding the impact of symptomatic skeletal events (SSEs) on health economics and patient-reported outcomes in men with castration-resistant prostate cancer (CRPC) and bone metastases from a clinical setting are lacking. Hence, this study aimed to quantify the effects of SSEs on health-care resource utilization (HRU), health-related quality of life (HRQoL) and pain in men with CRPC metastasized to bone. METHODS: This cohort study included men with CRPC and bone metastasis treated at a tertiary center during December 1996-July 2015. SSEs, including pathological fracture, radiation to bone, spinal cord compression and bone surgery, as well as HRU were identified retrospectively through medical records and clinical database. A subset of surviving patients completed Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Brief Pain Inventory-Short Form (BPI-SF) questionnaires. The incremental effect of SSEs on HRU was evaluated using multivariable generalized linear regression. Questionnaire scores were compared using effect sizes (ES); ES⩾0.33 indicated meaningful differences between SSE and non-SSE cohorts. Lower scores suggest lower HRQoL and pain. RESULTS: Of the 832 patients, 207 developed ⩾1 SSE (mean 1.5±0.8) during follow-up (median 2.1 years). Radiation to bone was the most common SSE (84.1%). SSE cohort had significantly higher emergency room (incidence rate ratio (IRR)=1.48; P=0.006), outpatient (IRR=1.17; P=0.005) and inpatient (IRR=1.74; P<0.001) visits. Of the 107 eligible survey patients, 103 (96.3%) responded. SSE cohort had lower mean FACT-P functional well-being (17.5 vs 19.8; P=0.158; ES=0.36), higher mean pain severity (2.5 vs 1.6; P=0.048; ES=0.47) and worst pain scores (3.6 vs 2.3; P=0.033; ES=0.50) compared with the non-SSE cohort, indicating meaningful differences between cohorts. CONCLUSIONS: This study demonstrated high economic and HRQoL burden of SSEs. The findings underscore the need for better supportive and disease-modifying treatments for these patients.
Authors: Peter A Elliott; George A Abdelsayed; Patrick S Kilday; Brian J Kim; Jeff M Slezak; Gary W Chien Journal: World J Urol Date: 2017-10-30 Impact factor: 4.226
Authors: Lisa Marie Ruppert; Erica Dayan Cohn; Niamh M Keegan; Abigail Bacharach; Sungmin Woo; Theresa Gillis; Howard I Scher Journal: JCO Oncol Pract Date: 2022-02-17
Authors: Arif Hussain; Candice Yong; Katherine H R Tkaczuk; Yi Qian; Jorge Arellano; C Daniel Mullins; Eberechukwu Onukwugha Journal: PLoS One Date: 2018-03-01 Impact factor: 3.752
Authors: Fernando Maluf; Andrey Soares; Guilherme Avanço; Aline Lury Hada; Ana Paula Garcia Cardoso; Arie Carneiro; Daniel Herchenhorn; Denis Leonardo Fontes Jardim; Fabio Augusto Schutz; Fabio Roberto Kater; Felipe Moraes Toledo Pereira; Fernando Sabino Marques Monteiro; Igor Alexandre Protzner Morbeck; João Francisco Navarro Reolon; Karine Martins da Trindade; Livia Maria Querino da Silvo Andrade; Lucas Mendes Nogueira; Renato Furoni; Ricardo Azze Natel; Rodolfo Borges Dos Reis; Rodrigo Nogueira Fogace; Vinicius Carrera Souza Journal: Int Braz J Urol Date: 2021 Mar-Apr Impact factor: 1.541
Authors: Roger von Moos; Michael Mark; Karin Ribi; Beat Thürlimann; Corinne Schär; Daniel Dietrich; Richard Cathomas; Ursina Zürrer-Härdi; Thomas von Briel; Sandro Anchisi; Pierre Bohanes; Veronika Blum; Philippe von Burg; Meinrad Mannhart; Clemens B Caspar Journal: BMC Cancer Date: 2021-02-19 Impact factor: 4.430
Authors: Neal Shore; Celestia S Higano; Daniel J George; Cora N Sternberg; Fred Saad; Bertrand Tombal; Kurt Miller; Jan Kalinovsky; XiaoLong Jiao; Krishna Tangirala; Oliver Sartor Journal: Prostate Cancer Prostatic Dis Date: 2020-05-13 Impact factor: 5.455